1. Scrip

Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism

 
• By Joseph Haas

Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.

Happy Hopeful Woman Looking at the Sunset by the Sea. Silhouette of a dreamer girl looking hopeful at the horizon
Analysts and NIAID director Fauci called the data significant and reason for optimism

News from Gilead Sciences Inc. and the US National Institute of Allergy and Infectious Diseases on 29 April about remdesivir in the treatment of COVID-19 produced a wave of optimism throughout financial markets based on the first evidence of a treatment benefit in patients sickened by the novel coronavirus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

 
• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.